Literature DB >> 21625790

[Ultrasound-guided core needle biopsy for the diagnosis of fibroepithelial breast tumors].

Marcos Desidério Ricci1, Paulo Gustavo Tenório do Amaral, Denis Seiiti Aoki, Hélio Rubens de Oliveira Filho, Walter da Silva Pinheiro, José Roberto Filassi, Edmund Chada Baracat.   

Abstract

PURPOSE: to evaluate the concordance rate of ultrasound-guided core needle biopsy followed by excisional biopsy in palpable breast lumps, suggestive of fibroepithelial tumors.
METHOD: a retrospective study included 70 biopsies with a histological diagnosis of fibroepithelial tumor in 67 out of 531 patients with breast lesions submitted to ultrasound-guided core needle biopsy with a high frequency (7.5 MHz) linear transducer, using an automatic Bard-Magnum gun and a 14-gauge needle. Cases with a diagnosis of fibroepithelial tumor by core needle biopsy or excisional biopsy and with a diagnosis of fibrosclerosis were included in the study. The agreement between the two biopsy methods was assessed using the Kappa coefficient.
RESULTS: excisional biopsy revealed 40 cases of fibroadenoma (57.1%), 19 cases of phyllodes tumor (27.2%), and 11 cases of fibrosclerosis (15.7%). The concordance rate for fibroadenoma was substantial (k = 0.68, 95%CI = 0.45 - 0.91), almost perfect for the phyllodes tumor (k = 0.81, 95%CI = 0.57 - 1.0), and moderate for fibrosclerosis (k = 0.58, 95%CI = 0.36 - 0.90).
CONCLUSIONS: the core needle biopsy is a minimally invasive method that has "substantial" to "almost perfect" concordance rate with excisional biopsy. Fibrosclerosis should be considered in the differential diagnosis of fibroepithelial tumors.

Entities:  

Mesh:

Year:  2011        PMID: 21625790     DOI: 10.1590/s0100-72032011000100004

Source DB:  PubMed          Journal:  Rev Bras Ginecol Obstet        ISSN: 0100-7203


  1 in total

1.  Core needle biopsy in fibroepithelial tumors: predicting factors for phyllodes tumors.

Authors:  Yedda Nunes Reis; Jonathan Yugo Maesaka; Carlos Shimizu; José Maria Soares-Júnior; Edmund Chada Baracat; José Roberto Filassi
Journal:  Clinics (Sao Paulo)       Date:  2021-04-16       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.